Short answer
MapLight Therapeutics, Inc. (MPLT) filed its Q3 2026 10-Q quarterly report on Nov 16, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$52M
- +36.7% YoY · +14.2% QoQ
- EPS (diluted)
- −$0.94
- +99.1% YoY · +28.8% QoQ
Source: XBRL data from the MapLight Therapeutics, Inc. (MPLT) Q3 2026 10-Q on SEC EDGAR. USD.
MapLight Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, with no product sales
- Operating margin not applicable, operating loss $55.3M vs $31.5M YoY
- R&D expenses $44.2M vs $27.1M, driven by clinical trials and employee costs
- Cash, equivalents and investments $463.4M; operating cash used $131.7M
- Outlook: cash expected to fund operations through 2028, further funding required thereafter
Risk Factors
- Newly triggered supply-chain risk: BIOSECURE Act enacted December 18, 2025 may affect a CDMO and restrict certain Chinese biotechnology suppliers
- Most materially updated regulatory risk: OBBBA signed July 4, 2025 may reduce ACA coverage and Medicaid enrollment
- Clinical risk: IRIS Phase 2 failed its primary endpoint in June 2026
- Operational risk: ML-007C-MA relies on limited single-source manufacturing suppliers
- Financial risk: $463.4 million cash, equivalents and investments expected to fund operations through 2028
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MapLight Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.